Amentum Holdings stock hits 52-week low at 17.88 USD

Amentum shares hit a 52-week low of $17.88, down 29.71% over one year, 36.28% year-to-date and 48% below their $38.11 peak. The company reported fiscal Q3 2026 adjusted EPS of $0.67, beating the $0.40 consensus, on roughly $3.5B in revenue, but modest growth and a muted 2027 outlook continue to weigh on sentiment. A $974M NASA maintenance and engineering contract and improved profitability provide offsets, while analyst targets range from $24 at UBS to $40 at Citizens.

Analysis

The market is discounting AMTM as an ex-growth government-services roll-up rather than valuing the earnings beat as durable. That distinction matters: margin and cash conversion can support deleveraging and equity re-rating, but only if the improvement is not principally merger-synergy timing, working-capital release, or mix shift toward lower-quality fixed-price work. The key KPI for the next 1-3 months is funded book-to-bill and organic revenue guidance; a sub-1.0x order cadence would validate the current multiple discount despite stronger near-term EPS.

NASA work is strategically useful but should not be extrapolated dollar-for-dollar into equity value. Large federal technical-services awards typically have long mobilization periods, modest initial revenue conversion, and margins below specialized classified/intelligence programs. The second-order beneficiary of continued civil-space and defense-services demand is KBR, which has greater space/intelligence exposure and a cleaner standalone growth narrative; AMTM needs evidence that its broader platform can convert awards into higher-margin cross-selling.

The contrarian setup is attractive only if leverage is falling faster than the market expects. At the current depressed price, even a modest multiple recovery could create asymmetric upside if management demonstrates sustained free-cash-flow conversion and raises rather than merely reiterates its medium-term outlook. Conversely, federal appropriations disruption, a continuing resolution that delays program starts, or another muted revenue outlook would keep AMTM trapped as a value screen rather than a catalyst-driven long over the next 6-12 months.

Key Decisions for Investors

• Keep AMTM on a catalyst watch rather than chase the 52-week-low print. Initiate a 50 bps starter long only after the next update shows organic-growth stabilization and funded book-to-bill at or above 1.0x; add if net leverage declines sequentially. Target $24-26 over 6-12 months, with a stop/reassessment below $16 or on a reduction in cash-flow guidance.
• Use a relative-value expression: long AMTM / short BAH in equal beta-adjusted dollars after confirmation of improving AMTM orders. The thesis is valuation convergence from integration synergies and deleveraging, while BAH faces a more mature growth and multiple profile; close if AMTM's revenue outlook remains below peer growth for two reporting periods.
• For investors requiring defined downside, consider 6-9 month AMTM $17.50/$25 call spreads only after earnings or a contract/backlog catalyst, rather than buying volatility ahead of an uncertain guidance event. The trade requires shares to recover above roughly $20-21 to work; avoid if implied volatility is elevated versus its post-earnings range.
• Monitor federal funding mechanics weekly: a prolonged continuing resolution or shutdown risk is a near-term reason to defer longs, as delayed contract starts and customer award decisions can pressure order conversion even when backlog remains intact.